Marinus Pharmaceuticals Inc (MRNS)
$1.475
+0.1
(+6.88%)▲
Insights on Marinus Pharmaceuticals Inc
Decreasing Revenue
Revenue is down for the last 2 quarters, 7.33M → 7.19M (in $), with an average decrease of 2.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -31.93M → -41.76M (in $), with an average decrease of 15.0% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 45.1% return, outperforming this stock by 126.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 238.3% return, outperforming this stock by 328.0%
Performance
- $1.35$1.50$1.48
8.78%
Downside
Day's Volatility :10.0%
Upside
1.33%
- $1.11$11.26$1.48
25.0%
Downside
52 Weeks Volatility :90.14%
Upside
86.86%
Returns
| Period | Marinus Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -85.18% | -0.4% | 0.0% |
6 Months | -77.48% | 9.6% | 0.0% |
1 Year | -82.38% | 3.9% | -1.3% |
3 Years | -89.71% | 12.8% | -22.1% |
Highlights
Market Capitalization | 75.8M |
Book Value | $0.31 |
Earnings Per Share (EPS) | -2.63 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -492.87% |
Return On Assets TTM | -38.19% |
Return On Equity TTM | -213.02% |
Revenue TTM | 31.0M |
Revenue Per Share TTM | 0.58 |
Quarterly Revenue Growth YOY | 0.4% |
Gross Profit TTM | -55.9M |
EBITDA | -126.1M |
Diluted Eps TTM | -2.63 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.19 |
EPS Estimate Next Year | -1.29 |
EPS Estimate Current Quarter | -0.62 |
EPS Estimate Next Quarter | -0.58 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 496.61%
Technicals Summary
Sell
Neutral
Buy
Marinus Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Marinus Pharmaceuticals Inc | -83.48% | -77.48% | -82.38% | -89.71% | -91.42% |
 Moderna, Inc. | -5.36% | 32.83% | -24.38% | -39.84% | 322.91% |
 Regeneron Pharmaceuticals, Inc. | -6.34% | 13.15% | 12.94% | 84.22% | 161.57% |
 Novo Nordisk A/s | -2.94% | 28.97% | 46.95% | 238.27% | 414.84% |
 Vertex Pharmaceuticals Incorporated | -3.87% | 8.77% | 20.15% | 83.53% | 128.04% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Marinus Pharmaceuticals Inc | NA | NA | 0.0 | -2.19 | -2.13 | -0.38 | NA | 0.31 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.77 | 25.77 | 1.46 | 45.22 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.13 | 46.13 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.39 | 28.39 | 0.53 | 16.72 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Marinus Pharmaceuticals Inc | Buy | $75.8M | -91.42% | NA | 0.0% |
Moderna, Inc. | Buy | $38.8B | 322.91% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.4B | 161.57% | 25.77 | 30.14% |
Novo Nordisk A/s | Buy | $551.3B | 414.84% | 46.13 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 128.04% | 28.39 | 36.68% |
Institutional Holdings
Suvretta Capital Management, LLC
9.78%BlackRock Inc
8.42%Eventide Asset Management, LLC
8.29%Franklin Resources Inc
7.02%Cormorant Asset Management, LLC
5.95%venBio Select Advisor LLC
5.76%
Corporate Announcements
Marinus Pharmaceuticals Inc Earnings
Marinus Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
Organization | Marinus Pharmaceuticals Inc |
Employees | 165 |
CEO | Dr. Scott N. Braunstein M.D. |
Industry | Health Technology |
